Boehringer Ingelheim

Sanofi expects Zantac arbitration case with Boehringer Ingelheim to be resolved early this year
Endpoints
Wed, 01/4/23 - 05:16 pm
Sanofi
Boehringer Ingelheim
Zantac
legal
Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M
Endpoints
Mon, 12/19/22 - 10:07 pm
Boehringer Ingelheim
Click Therapeutics
digital therapeutics
schizophrenia
Lilly and Boehringer's Jardiance Racks Up Another Type 2 Diabetes Win
BioSpace
Wed, 12/7/22 - 11:40 pm
Eli Lilly
Boehringer Ingelheim
type 2 diabetes
Jardiance
pediatri
Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease
Fierce Pharma
Sun, 11/6/22 - 01:44 pm
Eli Lilly
Boehringer Ingelheim
chronic kideny disease
Jardiance
Farxiga
AstraZeneca
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Pharmaphorum
Thu, 10/27/22 - 10:41 am
Boehringer Ingelheim
BI 1015550
IPH
Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway
BioSpace
Fri, 10/7/22 - 10:39 am
Boehringer Ingelheim
Surrozen
Wnt pathway
retinal diseases
R&D
Boehringer Ingelheim preps FDA submission with new data in rare pediatric lung disease
Endpoints
Tue, 09/6/22 - 05:00 pm
Boehringer Ingelheim
nintedanib
Ofev
Boehringer reports Phase III data for nintedanib in interstitial lung disease
Clinical Trials Arena
Tue, 09/6/22 - 10:45 am
Boehringer Ingelheim
clinical trials
nintedanib
interstitial lung disease
Boehringer Ingelheim finally has skin in the game, scoring its first dermatology FDA nod
Fierce Pharma
Fri, 09/2/22 - 12:19 pm
Boehringer Ingelheim
FDA
dermatology
GPP
Spevigo
In damage control mode, Perrigo clarifies that it's off the hook in key Zantac case
Fierce Pharma
Thu, 08/18/22 - 11:18 pm
Perrigo
Boehringer Ingelheim
GSK
legal
Zantac
Boehringer takes on antimicrobial resistance with Evotec, bioMérieux JV
Pharmaforum
Wed, 07/6/22 - 11:00 am
Boehringer Ingelheim
Evotec
Biomerieux
antimicrobial resistance
antibiotic resistance
Aurobac Therapeutics
Biopharma Investment in China is Thriving Amid U.S. Downturn
BioSpace
Tue, 07/5/22 - 11:52 pm
China
biotech
WuXi Biologics
Boehringer Ingelheim
Siemens Healthineers
AstraZeneca
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
BioSpace
Tue, 06/28/22 - 10:40 am
Boehringer Ingelheim
BiomX
biomarkers
microbiome
IBD
Boehringer Ingelheim to incubate biotechs with Hong Kong R&D leader
Endpoints
Fri, 06/17/22 - 09:51 am
Boehringer Ingelheim
R&D
Hong Kong
incubators
Boehringer Ingelheim Signs Option to Acquire Immunology Partner, Trutino Biosciences
BioSpace
Wed, 06/15/22 - 10:56 am
Boehringer Ingelheim
Trutino Biosciences
M&A
cancer
ASCO 2022 – the spirit of Rova-T struggles to live on
EP Vantage
Tue, 06/7/22 - 10:19 am
ASCO 2022
Rova-T
AbbVie
Harpoon Therapeutics
Amgen
Boehringer Ingelheim
Boehringer Ingelheim inks deal for targeted cancer antibodies from Singapore research org
Endpoints
Fri, 06/3/22 - 10:54 am
Boehringer Ingelheim
oncology
cancer
Singapore
R&D
Boehringer OKs $100M biobucks deal for hearing loss R&D project
Fierce Biotech
Wed, 04/13/22 - 10:38 am
Boehringer Ingelheim
hearing loss
Autigen
biobucks
Boehringer Ingelheim boosts R&D commitment, promises up to 15 new product launches by 2025
Endpoints
Tue, 04/5/22 - 11:31 pm
Boehringer Ingelheim
R&D
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
BioSpace
Wed, 03/16/22 - 11:20 pm
Eli Lilly
Boehringer Ingelheim
clinical trials
chronic kidney disease
empagliflozin

Pages